Skip to content

Medical emergency? What to do

Search for an HIV Vaccine Must Go On Says Expert in Light of Recent High-profile Merck Failure

3-RXPublished April 30, 20085 min read

Key points

  • According to a recent article published in The Independent (UK), most scientists involved in AIDS research believe that a vaccine against HIV is further away than ever with some admitting that effective immunization against the virus may never occur, according to an unprecedented poll conducted by the paper.
  • “The failures of the past twenty-five years provide greater understanding of this complex disease.
  • Mymetics’ success is based on proprietary “know-how” and key intellectual property in matters of antigen engineering and vaccine design that have enabled the company to engineer an acknowledged vaccine candidate in the fight against HIV/AIDS.
  • • Why have approaches for vaccines focusing on antibody mucosal IgA been overlooked by big pharma and other entities supporting HIV research?

According to a recent article published in The Independent (UK), most scientists involved in AIDS research believe that a vaccine against HIV is further away than ever with some admitting that effective immunization against the virus may never occur, according to an unprecedented poll conducted by the paper.

The article describes a mood of deep pessimism that has spread among the international community of AIDS scientists after the trial failure of a promising Merck vaccine last year. This was only the latest in a series of setbacks in the twenty-five-year struggle to develop an HIV vaccine. The article authors, Steve Connor and Chris Green, cite one of the major conclusions to emerge from the failed clinical trial of Merck’s promising prototype vaccine, is that an important animal model used for more than a decade in preclinical HIV testing on monkeys does not in fact work.

“The passion for an HIV vaccine resonates strongly among small pharma, whose often-overlooked approaches may now take center stage as the search for a viable HIV vaccine continues,” says Sylvain Fleury, PhD, Chief Scientific Officer and Director at Mymetics, a vaccine company focused on malaria and the human immunodeficiency virus (HIV/AIDS).

“The failures of the past twenty-five years provide greater understanding of this complex disease. Each advances vaccine design, which improves our knowledge and may benefit various research fields. Testing HIV vaccine efficacy has been difficult because there are no perfect animal models; non-human primates (monkeys) being the closest with limitations.”

According to Dr. Fleury, for decades scientists have pursued vaccines that induce an immune protection during infection events that take place after HIV transmission, meaning once the HIV has crossed the mucosal tissues and has already infected cells. Now, it is becoming more evident that acting on earlier transmission events might improve the chance of blocking or slowing down HIV transmission. Dr. Fleury believes that pursuing and furthering a mucosa approach, one that focuses on preventing early HIV entry into the organism during the first minutes or hours following exposure to the HIV virus, may be the key to achieving a viable vaccine. The mucosa approach has not yet been widely explored, making Mymetics a pioneer in its research, research that has so far shown promising pre-clinical results.

Mymetics’ success is based on proprietary “know-how” and key intellectual property in matters of antigen engineering and vaccine design that have enabled the company to engineer an acknowledged vaccine candidate in the fight against HIV/AIDS.

Topics for discussion:

• Did big pharma put “all their eggs in one basket” in developing an HIV vaccine?

• Why have approaches for vaccines focusing on antibody mucosal IgA been overlooked by big pharma and other entities supporting HIV research?

• Why might the mucosa approach for HIV vaccines, which elicits protection for preventing early infection within the first hours following exposure, hold hope for eradicating HIV?

• Why has it taken so long to develop a vaccine against HIV?

• Are there better animal models for clinical testing?

• What opportunities lie ahead for small pharma in this space now that Merck is no longer a contender?

• How does the Mymetics vaccine in development work to prevent infection?


About Dr. Sylvain Fleury, PhD, VP, Chief Scientific Officer, Director, Mymetics Corporation

Dr. Fleury was appointed Chief Scientific Officer of Mymetics Corporation in November 2003 and as a Director in January 2006. Prior to that, Dr. Fleury did academic research from 1993 to 2003 on immunology, AIDS, and lentivirus gene therapy in heart transplantation at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland. Dr. Fleury obtained his B.Sc. in Microbiology in 1985 from the University of Montreal (Canada), his M.Sc. in Virology in 1988 from the Institut Armand-Frappier (Laval, Canada), and his PhD in 1992 from the Clinical Research Institute of Montreal in Canada with Rafick Sekaly. During his PhD research, Dr. Fleury worked on the CD4 molecule, which is the primary HIV cellular receptor. Dr. Fleury completed his postgraduate studies in Bethesda (USA) at the NIAID, National Institutes of Health (NIH), with world-renowned immunologist Dr. Ronald N. Germain. Dr. Fleury is the recipient of several awards and prizes and has published articles in his field of study in several highly regarded scientific journals including Science, Cell, Nature, Nature Medicine, and Circulation.

About Mymetics Corporation
Mymetics is a biotechnology company developing prophylactic vaccines that combine innovative antigen engineering, minimal human protein homologies, and virosome technology through a license acquired from Pevion Biotech. Mymetics’ vaccine approach is focused on eliciting immune protection capable of interfering with late events of pathogen transmission, coupled, most importantly, with early events of pathogen transmission, such as preventing the entry across the mucosal tissues that are very often the primary entry door of most of the pathogens. Virosomes are biosynthetic vesicles representing reconstituted empty influenza virus envelopes that serve as a highly efficient vaccine delivery system with intrinsic adjuvant potential. The Company’s disease focus presently includes malaria and the human immunodeficiency virus (HIV).

Source: Investor Relations Group

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Keep reading

Cancer

Experimental drug shrinks cancer tumors

An experimental cancer drug successfully shrank tumors in patients with different kinds of cancer, including typically hard-to-treat lung cancers, according to a new study. Oncologists said the research was…

4 min read

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.